breast cancer detection Archives - Amazing Health Advances

How a Mammogram Actually Causes Breast Cancer

The AHA! Team — Fri, 12 Sep 2025 05:07:39 +0000

Abby Campbell via NaturalHealth365 – In reality, more and more studies are showing that a mammogram breast screening has some major flaws – which put women at serious health risk and actually increase the risk of cancer. An X-ray picture of the breast, called a mammogram, is heavily promoted as the ‘primary way to screen’ for breast cancer, according to Western medicine. Conventionally speaking, an annual detection screening is recommended as early as age 40 by both the American Cancer Society and the National Comprehensive Cancer Network, while the United States Preventive Services Task Force recommends screenings every other year starting at age 50. While mammogram guidelines differ amongst organizations, they all agree there are concerns about the test. Yet, disputes exist amongst experts when it comes to mammography detecting invasive breast cancer. So, the question remains: do the benefits outweigh the risks? In reality, more and more studies are showing that a mammogram breast screening has some major flaws – which put women at serious health risk and actually increase the risk of cancer. Strange logic: Zero-stage cancer detected but treated aggressively Ductal carcinoma in situ (DCIS) refers to the abnormal growth of cells forming a lesion between 1 and 1.5 centimeters in diameter. While this is not cancer, approximately 25 percent (60,000 cases) of all newly diagnosed breast cancer falls within this category each year. Because evidence indicates that less than half of DCIS cases progress to invasive cancer, some experts declare it should be reclassified as a non-cancerous condition. Additionally, they recommend a “watchful eye” for women who have this condition rather than invasive therapy. After all, why treat someone who doesn’t have cancer with chemotherapy or radiation – which places their immune systems at risk for a lifetime? However, mammography proponents claim they’re saving lives through early detection and treatment of DCIS. They view it as pre-cancerous or “stage zero cancer” and believe it could eventually cause harm if left untreated. Therefore, they recommend treating it in the same manner as invasive cancer with aggressive treatments. But is this right or fair? According to Time Magazine, “Cancer has a language problem … A 57-year old woman with low-grade DCIS that will almost certainly never become invasive hears the same word as the 34-year old woman who has metastatic malignancies that will kill her. That’s confusing to patients conditioned to treat every cancer diagnosis as an emergency in a world that still reacts to cancer as though it’s the beginning of the end.” The latest round of controversy was set off about DCIS treatment after a study was published by JAMA Oncology. After a 20-year analysis of 100,000 women who were diagnosed with DCIS, the mortality rate from breast cancer of these patients was the same as the general population at 3.3 percent. Radiation from mammogram screening is a breast cancer risk While several organizations like the Susan G. Komen for the Cure heavily promote mammograms for early screening for breast cancer, it’s ironic that mammogram machines put each woman at risk for the very thing they want to prevent. The ionizing radiation used to detect breast tumors is a risk factor for breast cancer development. Additionally, the crushing compression of this test on the breast tissue may potentially spread cancer if the cancer cells are present. After several studies, Cornell University determined people who are exposed to ionizing radiation emitted from machines like the mammogram machine place themselves at risk for breast cancer. They also stated, “… female breast tissue is highly susceptible to radiation effects” as it “is one of the most sensitive tissues to the carcinogenic action of ionizing radiation.” They also revealed that it takes a minimum of five to 10 years for radiation-induced breast cancer to develop. Finally, they concluded that greater levels of radiation exposure lead to a greater risk of breast cancer. Every time a woman is exposed to this form of radiation, she is placing herself at higher risk – especially if the screening is done when there is estrogen stimulation and tissue proliferation that occurs during monthly menstrual cycles. Prevention of breast cancer is better than detection While early detection of breast cancer can be done by mammogram screening, it is not the same as “prevention.” Lifestyle choices will help you prevent cancer or any chronic illness. Be sure to eat real whole and organic foods, drink plenty of fresh (clean) water, exercise regularly, get plenty of rest, and manage stress levels. Editor’s note: Discover the best ways to naturally reduce the risk of cancer, own the Stop Cancer Docu-Class created by NaturalHealth365 Programs. Sources for this article include: NIH.gov CDC.gov Nccn.org Time.com To read the original article click here.

The post How a Mammogram Actually Causes Breast Cancer appeared first on Amazing Health Advances.

New AI-Based Tool Improves the Diagnosis of Breast Cancer Tumors

AHA Publisher — Mon, 18 Oct 2021 07:00:11 +0000

Karolinska Institute via News-Medical – Researchers at Karolinska Institutet in Sweden have developed an AI-based tool that improves the diagnosis of breast cancer tumors and the ability to predict the risk of recurrence. The greater diagnostic precision can lead to more personalized treatment for the large group of breast cancer patients with intermediate risk tumors. The results are published in the scientific journal Annals of Oncology. Every year, around two million women globally develop breast cancer. In the diagnostic procedure, tissue samples of the tumor are analyzed and graded by a pathologist and categorized by risk as low (grade 1), medium (grade 2) or high (grade 3). This helps the doctor determine the most suitable treatment for the patient. “Roughly half of breast cancer patients have a grade 2 tumor, which unfortunately gives no clear guidance on how the patient is to be treated. Consequently, some of the patients are over-treated with chemotherapy while others risk being under-treated. It’s this problem that we’ve tried to resolve.” Yinxi Wang, Study First Author and Doctoral Student, Department of Medical Epidemiology and Biostatistics, Karolinska Institute Hospitals have recently started to make limited use of molecular diagnostics to improve the precision of breast cancer risk assessment, but these methods are often costly and time-consuming. The researchers at Karolinska Institutet have now developed and evaluated an AI (artificial intelligence)-based method for tissue analysis. The study shows that the AI-based method can further divide the patients with grade 2 tumors into two sub-groups, one high-risk and one low-risk, that are clearly distinguishable in terms of the recurrence risk. “One big advantage of the method is that it’s cost-effective and fast, since it’s based on microscope images of dyed tissue samples, which is already part of hospital procedure,” says co-last author Johan Hartman, professor of pathology at the Department of Oncology-Pathology, Karolinska Institutet, and pathologist at the Karolinska University Hospital. “It enables us to offer this type of diagnosis to more people and improves our ability to give the right treatment to any one patient.” The AI model has been trained to recognize characteristics of high-resolution microscopic images from patients classified with grade 1 and grade 3 tumors. The study is based on an extensive microscopic image bank of 2,800 tumors. “It’s fantastic that deep learning can help us develop models that don’t just reproduce what specialist doctors do today, but also enable us to extract information beyond the scope of the human eye,” says co-last author Mattias Rantalainen, associate professor and research group leader at the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet. The method is not yet ready for clinical application, but a regulatorily approved product is under development by a newly started company, Stratipath AB, which is supported by KI Innovations. The researchers will now be further evaluating the method with the aim to have a product out on the market by 2022. To read the original article click here.

The post New AI-Based Tool Improves the Diagnosis of Breast Cancer Tumors appeared first on Amazing Health Advances.

New Technology Detects Breast Cancer Using Tears

AHA Publisher — Fri, 26 Jun 2020 07:00:48 +0000

Kobe University via News-Medical Net – Kobe University and System Instruments Co., Ltd. researchers have developed TearExo®; new technology to detect breast cancer using the exosomes found in tears as biomarkers. Exosomes are a subtype of extracellular vesicles. Research team members included Professor TAKEUCHI Toshifumi (Kobe University Graduate School of Engineering), Project Professor TANINO Hirokazu and Professor SASAKI Ryohei (both of Kobe University Hospital), and Mr HAMADA Kazuyuki (System Instruments Co., Ltd.). This research was mainly conducted by researchers at Kobe University’s Medical Device Fabrication Engineering Center (Director: Professor MUKAI Toshiji). It is hoped that this technology can make a great contribution towards people’s health by enabling prompt cancer detection. This research was first published online on March 10, 2020 in the Journal of the American Chemical Society and was featured on the journal cover. Main Points TearExo® uses the world’s first chemical nano-processing technology to detect exosomes in a very small amount of bodily fluid, demonstrating extremely high sensitivity and smooth operability, without the need for pretreatments and detection reagents. TearExo® enables non-invasive breast cancer testing to be conducted using tear fluid samples that can be easily self-collected by the patient. The researchers demonstrated a new liquid biopsy methodology for early cancer detection using the exosomes in tear fluid as biomarkers. This was realized through an ‘automatic exosome analyzer’; a highly sensitive assay to measure exosomes, which enables bodily fluid tests to be conducted quickly and easily. Research Background Currently, imaging-based screening methods such as mammography are used to detect breast cancer. However, these medical devices are often large and it takes time to obtain the results, as at least two specialists need to interpret the images. This imposes a heavy burden on the patient. Recently liquid biopsies, where the extracellular vesicle exosomes found in patients’ bodily fluids are used as biomarkers to detect cancer, have gained attention as a possible alternative. Liquid biopsies are noninvasive and reduce the burden on the patient. It is hoped that they would improve both cancer testing rates and early cancer detection rates. It has been reported that exosomes are involved in cancer metastasis and malignant development. Therefore exosomes are often the target of liquid biopsies as they are considered to be extremely important markers for diagnosing cancer. However, it is difficult to conduct a prompt analysis using regular exosome analysis methods because they require cumbersome preprocessing. If a new, convenient and highly sensitive method for detecting cancer cell-related exosomes in bodily fluids were to be implemented, it would provide an extremely powerful cancer screening method. Research Methodology Principle TearExo® consists of a fluorescent exosome sensing chip and an automatic exosome analyzer. The fluorescent exosome sensing chip was constructed by placing an antibody and a fluorescent reporter molecule in a 100nm nanocavity formed on a glass chip. The antibody recognizes the surface proteins of exosomes and the fluorescent reporter molecule can be used to read the exosomes’ binding with the antibody based on changes in the fluorescence. With the automatic exosome analyzer, the researchers achieved a rapid, ultra-sensitive assay (about 1000 times more sensitive than current immunoassays) capable of detecting 50 exosomes in 100µL of fluid in ten minutes, without the need for the lengthy pretreatment required in the past. Detecting Cancer from Tear Fluid Tear fluid was sampled from breast cancer patients and healthy donors via Schirmer tests, whereby a small strip of filter paper is used to collect the tear fluid. TearExo® was used to measure the exosomes in these tear fluid samples and analyze the pattern of the surface proteins’ composition (principal component analysis). A clear difference was found between the samples obtained from healthy donors and those from breast cancer patients, demonstrating that tear fluid can be used to detect breast cancer. Exosome composition is different before and after mastectomy; after surgery the composition is the same as that found in healthy people. This shows that TearExo® could also be used to check and monitor patients’ post-treatment recovery, as well as for initial cancer detection.For the first time in the world, this research demonstrated that cancer can be detected using tear fluid. Further Research Exosome analysis of clinical samples will be conducted on a larger scale to determine the specificity and sensitivity of this method of breast cancer diagnosis. After that, there are plans to establish a venture company within the next year and apply to Japan’s PMDA (Pharmaceuticals and Medicals Device Agency) for the approval of TearExo® as an in vitro diagnostic device. To read the original article click here.

The post New Technology Detects Breast Cancer Using Tears appeared first on Amazing Health Advances.